B. Psaila, A. Petrovic, L. K. Page, J. Menell, M. Schonholz et al., Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP) : study of 40 cases, Blood, vol.114, issue.23, pp.4777-83, 2009.

Y. Liang, L. Zhan, J. Gao, D. Hu, and Y. Ai, Rituximab for children with immune thrombocytopenia : a systematic review, Plos One, vol.7, issue.5, p.36698, 2012.

B. Bader-meunier, N. Aladjidi, F. Bellmann, F. Monpoux, B. Nelken et al., Rituximab therapy for childhood Evans syndrome, Haematologica, vol.92, issue.12, pp.1691-1695, 2007.

P. Quartier and A. Et, Treatment of childhood autoimmune haemolytic anaemia with rituximab, Lancet, vol.358, issue.9292, pp.1511-1513, 2001.

M. Pasquet, N. Aladjidi, C. Guiton, M. F. Courcoux, M. Munzer et al., Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience, Br J Haematol, vol.164, issue.2, pp.266-71, 2014.

M. Pasquet, N. Aladjidi, C. Guitton, T. Leblanc, and Y. Perel, Recommandations d'utilisation des agonistes du récepteur de la thrombopoïétine dans le purpura thrombopénique immunologique de l'enfant et de l'adolescent, Rev Onc Hematol Pedia, vol.3, issue.1, 2015.

G. R. Buchanan, The nontreatment of childhood idiopathic thrombocytopenic purpura, Eur J Pediatr, vol.146, issue.2, pp.107-119, 1987.

J. S. Lilleyman, Management of childhood idiopathic thrombocytopenic pupura, British Journal of Haematology, vol.105, pp.871-875, 1999.

B. Godeau and N. Aladjidi, Purpura thrombopénique immunologique de l'adulte et de l'enfant. Protocole national de diagnostic et de soins (PNDS), 2017.

M. Michel and N. Aladjidi, Anémie hémolytique auto-immune de l'adulte et de l'enfant. Protocole national de diagnostic et de soins (PNDS), 2017.

H. King and A. Et, Susceptibility to infection after splenectomy performed in infancy, Ann Surg, vol.136, pp.239-281, 1952.

F. Rodeghiero, R. Stasi, and T. Gernsheimer, Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children : report from an international working group, Blood, vol.113, pp.2386-93, 2009.

B. Godeau, Les thrombopénies immunologiques : physiopathologie et traitements. Bull. Acad. Natle Méd, vol.2, pp.407-417, 2013.

R. Stasi and A. Et, Idiopathic thrombocytopenic purpura : Current concepts in pathophysiology and management, ThrombHaemost, vol.99, pp.4-13, 2008.

G. Moulis and . Al, Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France, Blood, vol.124, pp.3308-3315, 2014.

G. R. Buchanan, Bleeding signs in children with idiopathic thrombocytopenic purpura, J Pediatr Hematol Oncol, vol.25, issue.1, pp.42-46, 2003.

H. Donato and A. Et, Splenectomy and Spontaneous Remission in Children With Chronic Idiopathic Thrombocytopenic Purpura, Pediatr Blood Cancer, vol.47, pp.737-739, 2006.

Y. Yoshida, Historical review. The light and shadow of Paul Kaznelson: his life and contribution to hematology, Ann Hematol, vol.87, pp.877-879, 2008.

T. Kühne, Splenectomy in Children With Idiopathic Thrombocytopenic Purpura : A Prospective Study of 134 Children From the Intercontinental Childhood ITP Study Group, Pediatr Blood Cancer, vol.49, pp.829-834, 2007.

S. Srinivasan and . Al, Role of Splenectomy in Chronic Idiopathic Thrombocytopenic, Purpura. JAPI, vol.51, 2003.

E. Rijcken, Laparoscopic splenectomy for medically refractory immune thrombocytopenia (ITP) : A retrospective cohort study on longtime response predicting factors based on consensus criteria, International Journal of Surgery, vol.12, pp.1428-1433, 2014.

B. Godeau and A. Et, Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura:results of a prospective multicenter phase 2 study, Blood, vol.112, pp.999-1004, 2008.

K. R. Carson and A. , Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients : a report of 57casesfromtheResearchonAdverseDrug Events and Reports project, Blood, vol.113, pp.4834-4840, 2009.

J. B. Bussel, Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura, N Engl J Med, vol.357, issue.22, pp.2237-2284, 2007.

B. S. Poudyal, Safety and Efficacy of Azathioprine as a Second Line Therapy for Primary Immune Thrombocytopenic Purpura, JNMA J Nepal Med Assoc, vol.55, issue.203, pp.16-21, 2016.

M. Miano, Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology/oncology, Br J Haematol, vol.175, issue.3, pp.490-495, 2016.

, Mycophenolate mofetil and Sirolimus as second or further line treatment in children with chronic refractory Primitive or Secondary Autoimmune Cytopenias : a single centre experience, BJH, vol.171, issue.2, pp.247-253, 2015.

B. Fresneau, A. Petit, M. F. Courcoux, M. D. Tabone, A. Auvrignon et al., Vinblastine in the treatment of children and adolescents with refractory immune thrombocytopenia, American journal of hematology, vol.86, issue.9, pp.785-792, 2011.

O. Roche, N. Aladjidi, J. Rakotonjanahary, G. Leverger, T. Leblanc et al., Evaluation of the efficiency of hydroxychloroquine in treating children with immune thrombocytopenia (ITP), 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01815546

C. Neunert and A. Et, The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia, Blood, vol.117, pp.4190-4207, 2011.

M. Becheur, B. Bouslama, H. Slama, and N. E. Toumi, Anémies hémolytiques auto-immunes de l'enfant. Revue générale, Transfusion Clinique et Biologique, vol.22, pp.291-298, 2015.

N. Aladjidi, G. Leverger, and A. , Épidémiologie et prise en charge des anémies hémolytiques aiguës et chroniques de l'enfant. Archives de pédiatrie 13, pp.511-521, 2006.

P. Quartier and A. Et, Treatment of childhood autoimmune haemolytic anaemia with rituximab, Lancet, vol.358, issue.9292, pp.1511-1513, 2001.

D. Bodet, N. Aladjidi, and A. Et, Splénectomie pour anémie hémolytique auto-immune et syndrome d'Evans de l'enfant en France : à propos de 37 observations, Congrès SFH, 2013.

C. Rafael, Mabthera (Rituximab) in the Treatment of 34 Adult Patients with Refractory Autoimmune Hemolytic Anemia (AIHA), Blood, vol.104, p.1619, 2004.

N. Aladjidi, H. Fernandes, T. Leblanc, A. Vareliette, F. Rieux-laucat et al., Evans Syndrome in Children: Long-Term Outcome in a Prospective French National Observational Cohort. Frontiers in pediatrics, vol.3, p.79, 2015.

M. Miano, How I manage Evans Syndrome and AIHA cases in children, British Journal of Haematology dec, vol.172, issue.4, pp.524-534, 2015.

B. Bader-meunier, N. Aladjidi, F. Bellmann, F. Monpoux, B. Nelken et al., Rituximab therapy for childhood Evans syndrome, Haematologica, vol.92, issue.12, pp.1691-1695, 2007.

M. Mahévas, B cell depletion in immune thrombocytopenia reveals splenic longlived plasma cells, The Journal of Clinical Investigation, vol.123, issue.1, pp.432-442, 2013.

U. Ramenghi and . Al, Splenectomy in Children With Chronic ITP: Long-Term Efficacy and Relation Between its Outcome and Responses to Previous Treatments, Pediatr Blood Cancer, vol.47, pp.742-745, 2006.

B. Delaitre, Splenectomie laparoscopique pour maladies hématologiques. Etude de 275 cas, Ann Chir, vol.125, pp.522-529, 2000.

H. King and A. Et, Susceptibility to infection after splenectomy performed in infancy, Ann Surg, vol.136, pp.239-281, 1952.

R. J. Holdsworth, A. D. Irving, and A. Cuschieri, Postsplenectomy sepsis and its mortality rate : actual versus perceived risks, Br J Surg, vol.78, pp.1301-1309, 1991.

S. Benoist, Les complications à moyen et long terme de la splénectomie, Annales de chirurgie, vol.125, issue.4, pp.317-324, 2000.

G. L. Cullingford, D. N. Watkins, and A. D. Watts,

D. F. Mallon, Severe late postsplenectomy infection, Br J Surg, vol.78, pp.716-737, 1991.

V. V. Likhite, Immunological impairment and susceptibility to infection after splenectomy, JAMA, vol.236, issue.12, pp.1376-1383, 1976.

Y. Sigurdur and A. Et, Long-term risks after splenectomy among 8149 cancer-free American veterans: a cohort study with up to 27 years follow-up, Haematologica. February, vol.99, pp.392-398, 2014.

S. Aronis, H. Platokouki, M. Avgeri, H. Pergantou, and D. Keramidas, Retrospective evaluation of longterm efficacy and safety of splenectomy in chronic idiopathic thrombocytopenic purpura in children, Acta Paediatr, vol.93, pp.638-642, 2004.

F. Rodeghiero, Is splenectomy still the gold standard for the treatment of chronic ITP ?, Am J Hematol, vol.83, issue.2, p.91, 2008.

F. Palandri and . Al, Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments ? A monocentric study in the outpatient setting during 35 years, Am J Hematol, vol.91, issue.4, pp.267-72, 2016.

C. Law and . Al, High-dose intravenous immune globulin and the response to splenectomy in patient with idiopathic thrombocytopenic purpura, N Engl J Med, vol.336, pp.1494-1502, 1997.

H. Ojim and . Al, Factors Predicting Long-term Responses to Splenctomy in Patients with Idiopathic Thrombocytopenic Purpura, World J Surg, vol.30, pp.553-559, 2006.

K. , Scintigraphic prediction of therapeutic outcomes of splenectomy in patients with thrombocytopenia, Annals of Nuclear Medicine, vol.17, issue.2, pp.161-164, 2003.

R. L. Friedman, J. R. Hiatt, and J. L. Korman, Laparoscopic or open splenectomy for hematologic disease : which approach is superior?, JAm Coll Surg, vol.185, pp.49-54, 1997.

D. L. Posey and C. Marks, Overwhelming postsplenectomy sepsis in childhood, Am J Surg, vol.145, pp.318-339, 1983.